Litigation

Recent Posts

Avandia Off Market In Europe; FDA To Restrict Its Use, Orders Probe of GSK Study
Posted on 23 Sep 2010 by Tom Moylan

(Mealey's) The European Medicines Agency (EMA) on Sept. 23 recommended that the marketing authorization for GlaxoSmithKline PLC's (GSK) controversial anti-diabetes drug Avandia be suspended, and the Food and Drug Administration simultaneously... Read More

Tags: diabetes drug , EMA , European Medicines Agency , drugs & devices , Food and Drug Administration , Actos , rosiglitazone , TIDE study , Thiazolidinedione Intervention With Vitamin D Evaluation study , FDA , Litigation , Committee for Medicinal Products for Human Use , GSK , GlaxoSmithKline , pioglitazone , RECORD clinical trial , stroke , Avandia , Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia clinical trial , heart attack

Glaxo Takes $2.36 Billion Charge On Legal Costs
Posted on 15 Jul 2010 by LexisNexis Litigation Resource Community Staff

LONDON - (AP) Pharmaceutical company GlaxoSmithKline said Thursday it expects to take a $2.36 billion charge against second-quarter earnings for the costs of settling court cases over the antidepressant Paxil and diabetes drug Avandia. The company said... Read More

Tags: diabetes drug , European Medicines Agency , birth defects , Paxil , settlements , U.S. Food and Drug Administration , Apotex , Litigation , GSK , GlaxoSmithKline , lawsuit , pharmaceutical , antidepressant , Avandia

Lawsuits Follow Diabetes Drug Actos' Link To Cancer Risk
Posted on 9 Aug 2011 by LexisNexis Litigation Resource Community Staff

TRENTON, N.J. - (AP) The maker of the world's best-selling diabetes drug is facing hundreds of lawsuits and likely a big sales drop as suspicion grows that taking the pill for more than a year raises the risk of bladder cancer. In June, Takeda Pharmaceuticals... Read More

Tags: diabetes drug , lawsuits , European Medicines Agency , Weitz &amp , Food and Drug Administration , Luxenberg , Actos , Januvia , Type 2 diabetes , FDA , bladder cancer , Vioxx , Diabetes Care , Merck , Litigation , diabetes , Avandia